Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C

Table 2 Patients characteristics related to core mutation type, univariate analysis

Characteristics	Patients withDW-type infectionn = 13	Patients with R70Q/H and/or L91Msubstitutions n =95	Patients withL91M substitutionn = 40	Patients with R70Q/H substitution n = 8	P value1
Age (yr)	51.5	53.6	53.3	50	a = 0.607
median	(29.1-66.54)	(22.1-68.3)	(24.4-67.3)	(33.8-58.8)	b = 0.694
					c = 0.860
Gender	7 (53.8)	57 (60)	22 (55)	5 (62.5)	a = 0.767
Female (%)					b = 1.000
					c = 1.000
Residence	11 (84.6)	67 (70.5)	33 (82.5)	5 (62.5)	a = 0.509
Urban (%)					b = 1.000
					c = 0.325
Baseline ALT (mg/dL)	94	76	78	67	a = 0.592
median	(3-235)	(16-890)	(17-890)	(54-197)	b = 0.849
					c = 1.000
Baseline HCV-RNA (log10IU/mL), median	6.25	6.05	6.05	6.3	a = 0.966
	(4.15-6.9)	(4.15-7.3)	(4.1-7.3)	(5.2-7.1)	b = 1.000
					c = 0.414
Mild/moderate fibrosis (F1 + F2, %)	4 (57.1)	34 (58.6)	14 (58.3)	4 (57.14)	a = 0.881
					b = 0.925
					c = 0.283
IL28B CC (%)	6 (46.2)	13 (13.7)	8 (20.0)	1 (12.5)	a = 0.011
					b = 0.080
					c = 0.174
RVR (%)	6 (46.2)	8 (8.4)	4 (10.0)	0 (0.0)	a = 0.002
					b = 0.009
					c = 0.005
EVR (%)	10 (76.9)	33 (34.7)	15 (37.5)	3 (37.5)	a = 0.005
					b = 0.024
					c = 0.164
SVR (%)	10 (76.9)	32 (33.7)	15 (37.5)	2 (25.0)	a = 0.005
					b = 0.024
					c = 0.032

¹P value symbols a, b, c: cases from each category type of viral substitutions (columns 3, 4, 5) vs cases without viral mutation [double wild-type (DW)-type - column 2]. HCV: Hepatitis C virus; SVR: Sustained virological response; EVR: Early virological response; RVR: Rapid virologic response.